{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:32:06Z","timestamp":1762324326385,"version":"3.37.3"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0202954","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T19:03:18Z","timestamp":1535569398000},"page":"e0202954","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Extending the functional characteristics of naturally occurring autoantibodies against \u03b2-Amyloid, Prion Protein and \u03b1-Synuclein"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4897-6972","authenticated-orcid":true,"given":"Alexandra","family":"Albus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Philipp","family":"Bach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Burg-Roderfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marit","family":"J\u00f6rdens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Kirchhein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Kronimus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Mengel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"Zerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Dodel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,8,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.pathol.1.110304.100113","article-title":"Neurodegenerative diseases. new concepts of pathogenesis and their therapeutic implications","volume":"1","author":"DM Skovronsky","year":"2006","journal-title":"Annual review of pathology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1749-6632.1993.tb23043.x","article-title":"The C-terminus of the beta protein is critical in amyloidogenesis","volume":"695","author":"JT Jarrett","year":"1993","journal-title":"Annals of the New York Academy of Sciences"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nn1372","article-title":"Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function","volume":"8","author":"JP Cleary","year":"2005","journal-title":"Nature neuroscience"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000258724","article-title":"Neuroimmunomodulation in the pathogenesis of Alzheimer's disease","volume":"17","author":"I Morales","year":"2010","journal-title":"Neuroimmunomodulation"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1126\/science.1675487","article-title":"Molecular biology of prion diseases","volume":"252","author":"SB Prusiner","year":"1991","journal-title":"Science (New York, N.Y."},{"key":"ref6","first-page":"765","article-title":"Pathogenesis of prion diseases. current status and future outlook","volume":"4","author":"A Aguzzi","year":"2006","journal-title":"Nature reviews"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/nan.12066","article-title":"Dysfunction of the PI3K-Akt-GSK-3 pathway is a common feature in cell culture and in vivo models of prion disease","volume":"40","author":"D Simon","year":"2014","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrn1199","article-title":"The role of alpha-synuclein in Parkinson's disease. insights from animal models","volume":"4","author":"E Maries","year":"2003","journal-title":"Nature reviews"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1021\/bi030086j","article-title":"Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease","volume":"42","author":"MJ Volles","year":"2003","journal-title":"Biochemistry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1042\/BJ20150617","article-title":"Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease","volume":"471","author":"A Gustot","year":"2015","journal-title":"Biochem J"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1212\/WNL.57.5.801","article-title":"Reduced levels of amyloid beta-peptide antibody in Alzheimer disease","volume":"57","author":"Y Du","year":"2001","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1471-4159.2006.04365.x","article-title":"Autoantibodies to alpha-synuclein in inherited Parkinson's disease","volume":"101","author":"KK Papachroni","year":"2007","journal-title":"Journal of neurochemistry"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"12858","DOI":"10.1074\/jbc.M111.255836","article-title":"Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity","volume":"287","author":"X Wei","year":"2012","journal-title":"The Journal of biological chemistry"},{"article-title":"Autoantibodies","year":"2013","author":"Y Shoenfeld","key":"ref14"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.5962\/bhl.title.8281","article-title":"Clonal Selection Theory of Acquired Immunity","author":"F.M Burnet","year":"1959"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3389\/fimmu.2017.00872","article-title":"Defining Natural Antibodies","volume":"8","author":"NE Holodick","year":"2017","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1073\/pnas.81.8.2494","article-title":"Ly-1 B cells. functionally distinct lymphocytes that secrete IgM autoantibodies","volume":"81","author":"K Hayakawa","year":"1984","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1084\/jem.161.6.1554","article-title":"Progenitors for Ly-1 B cells are distinct from progenitors for other B cells","volume":"161","author":"K Hayakawa","year":"1985","journal-title":"J Exp Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0531-5565(02)00029-3","article-title":"Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals","volume":"37","author":"ME Weksler","year":"2002","journal-title":"Experimental gerontology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.0b013e31827b90d1","article-title":"Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease","volume":"80","author":"D Besong-Agbo","year":"2012","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e64649","DOI":"10.1371\/journal.pone.0064649","article-title":"Altered serum IgG levels to alpha-synuclein in dementia with Lewy bodies and Alzheimer's disease","volume":"8","author":"NK Koehler","year":"2013","journal-title":"PloS one"},{"key":"ref22","first-page":"98","article-title":"Immunotherapy in prion disease","volume":"9","author":"Y Roettger","year":"2012","journal-title":"Nature reviews"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1742-2094-10-5","article-title":"Mechanisms of action of naturally occurring antibodies against beta-amyloid on microglia","volume":"10","author":"M Gold","year":"2013","journal-title":"Journal of neuroinflammation"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e67743","DOI":"10.1371\/journal.pone.0067743","article-title":"Prion peptide uptake in microglial cells\u2014the effect of naturally occurring autoantibodies against prion protein","volume":"8","author":"Y Roettger","year":"2013","journal-title":"PloS one"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e63162","DOI":"10.1371\/journal.pone.0063162","article-title":"Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro","volume":"8","author":"S Cattepoel","year":"2013","journal-title":"PLoS ONE"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.neuropharm.2016.02.015","article-title":"Naturally occurring autoantibodies against A\u03b2 oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin","volume":"105","author":"T Wang","year":"2016","journal-title":"Neuropharmacology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1523\/JNEUROSCI.4401-10.2011","article-title":"Naturally occurring autoantibodies against beta-amyloid. investigating their role in transgenic animal and in vitro models of Alzheimer's disease","volume":"31","author":"R Dodel","year":"2011","journal-title":"J Neurosci"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"27638","DOI":"10.1074\/jbc.M113.463273","article-title":"Synthetic dimeric Abeta(28\u201340) mimics the complex epitope of human anti-Abeta autoantibodies against toxic Abeta oligomers","volume":"288","author":"AM Roeder","year":"2013","journal-title":"The Journal of biological chemistry"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1038\/tp.2012.151","article-title":"Naturally occurring autoantibodies interfere with beta-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer's disease 24 h after single treatment","volume":"3","author":"D Mengel","year":"2013","journal-title":"Translational psychiatry"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e0164953","DOI":"10.1371\/journal.pone.0164953","article-title":"Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia","volume":"11","author":"Y Kronimus","year":"2016","journal-title":"PLoS ONE"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jnr.20886","article-title":"Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide","volume":"84","author":"G Istrin","year":"2006","journal-title":"Journal of neuroscience research"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.14573\/altex.2009.2.83","article-title":"The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation","volume":"26","author":"A Henn","year":"2009","journal-title":"Altex"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/jnr.490310405","article-title":"An immortalized cell line expresses properties of activated microglial cells","volume":"31","author":"V Bocchini","year":"1992","journal-title":"J Neurosci Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1742-2094-7-90","article-title":"Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease","volume":"7","author":"J Magga","year":"2010","journal-title":"Journal of neuroinflammation"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/09687860500449994","article-title":"The prion protein and lipid rafts","volume":"23","author":"DR Taylor","year":"2006","journal-title":"Molecular membrane biology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1007\/s00018-007-7217-5","article-title":"Physiological and pathological properties of alpha-synuclein","volume":"64","author":"GK Tofaris","year":"2007","journal-title":"Cell Mol Life Sci"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","article-title":"Amyloid precursor protein processing and Alzheimer's disease","volume":"34","author":"RJ O'Brien","year":"2011","journal-title":"Annual review of neuroscience"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood","volume":"5","author":"R Barbour","year":"2008","journal-title":"Neuro-degenerative diseases"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4614-3461-0_11","article-title":"Control of B cells expressing naturally occurring autoantibodies","volume":"750","author":"JL Pasquali","year":"2012","journal-title":"Advances in experimental medicine and biology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"JM Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease","volume":"370","author":"RS Doody","year":"2014","journal-title":"The New England journal of medicine"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"S Salloway","year":"2014","journal-title":"The New England journal of medicine"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"J Sevigny","year":"2016","journal-title":"Nature"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0202954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T01:50:24Z","timestamp":1588989024000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0202954"}},"subtitle":[],"editor":[{"given":"Roberto","family":"Chiesa","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,8,29]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0202954","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2018,8,29]]}}}